Number
|
149
|
131
|
18
| |
Age, years, mean (SD)
|
58.15 (12.58)
|
57.60 (12.71)
|
62.22 (11.01)
|
0.11
|
Female, n (%)
|
123 (82.6)
|
108 (82.4)
|
15 (83.3)
|
0.61
|
Disease duration, years, median (IQR)
|
13.00 (8.00; 21.00)
|
13.00 (8.00; 20.50)
|
13.50 (8.50; 30.75)
|
0.41
|
Previous anti-TNFα failures, n (%)
|
30 (20.1)
|
26 (19.9)
|
4 (22.2)
|
0.51
|
Positive ACPA and/or RF, n (%)
|
76 (51.0)
|
65 (49.6)
|
11 (61.1)
|
0.36
|
Smokers or ex-smokers, n (%)
|
39 (26.2)
|
35 (26.7)
|
4 (22.2)
|
0.47
|
TSS progression per year before baseline, median (IQR)
|
8.00 (5.00; 11.63)
|
7.32 (5.00; 11.10)
|
10.25 (7.38; 15.50)
|
0.02
|
ADA treatments, n (%)
|
56 (37.6)
|
48 (36.6)
|
8 (44.4)
|
0.59
|
ETA treatments, n (%)
|
93 (62.4)
|
83 (63.4)
|
10 (55.6)
|
0.59
|
Low dose biologic, n (%)
|
103 (69.1)
|
89 (67.9)
|
14 (77.8)
|
0.40
|
Concurrent DMARD use, n (%)
|
76 (51.0)
|
66 (50.4)
|
10 (55.6)
|
0.68
|
PDN daily dose, mg, median (IQR)
|
1.00 (0.74; 2.00)
|
1.00 (0.60; 2.00)
|
1.50 (0.75; 2.00)
|
0.99
|
TSS progression at the 24-month follow up, median (IQR)
|
0 (0)
|
0 (0)
|
2.00 (2.00; 14.00)
|
<0.01
|
Baseline
| | | | |
HAQ, mean (SD)
|
0.74 (0.40)
|
0.73 (0.41)
|
0.87 (0.25)
|
0.08
|
DAS28, median (IQR)
|
2.21 (1.92; 2.38)
|
2.24 (1.85; 2.38)
|
2.05 (2.05; 2.38)
|
0.53
|
CRP, mg/L, median (IQR)
|
3.00 (1.00; 4.00)
|
3.00 (1.00; 4.00)
|
1.00 (1.00; 4.00)
|
0.24
|
TJC, median (IQR)
|
1 (0; 2)
|
1 (0; 2)
|
1 (1; 1)
|
0.70
|
SJC, median (IQR)
|
0 (0)
|
0 (0)
|
0 (0)
|
–
|
Patient-VAS, mm, median (IQR)
|
20 (15; 20)
|
20 (10; 30)
|
20 (0)
|
0.23
|
Follow up, 24 months
| | | | |
HAQ, median (IQR)
|
0.74 (0.39)
|
0.73 (0.40)
|
0.85 (0.23)
|
0.18
|
DAS28, median (IQR)
|
2.16 (1.80; 2.43)
|
2.18 (1.80; 2.63)
|
1.85 (1.82; 2.42)
|
0.52
|
CRP, mg/L, median (IQR)
|
2.00 (1.00; 3.00)
|
2.00 (1.00; 3.00)
|
2.00 (2.00; 3.00)
|
0.29
|
TJC, median (IQR)
|
1 (0; 2)
|
1 (0; 2)
|
0 (0; 1)
|
0.24
|
SJC, median (IQR)
|
0 (0)
|
0 (0)
|
0 (0)
|
–
|
Patient-VAS, mm, median (IQR)
|
20 (10; 30)
|
20 (10; 30)
|
33 (28; 35)
|
0.01
|
Change between baseline and 24-month follow up
|
HAQ, median (IQR)
|
0 (−0.10; 0.07)
|
0 (−0.11; 0.07)
|
0.01 (−0.05; 0.05)
|
0.56
|
DAS28, mean (SD)
|
−0.13 (0.55)
|
0 (0.58)
|
−0.02 (0.30)
|
0.63
|
CRP, mg/L, median (IQR)
|
0 (−2.00; −2.00)
|
0 (−3.00; 2.00)
|
1.00 (−1.00; 1.00)
|
0.11
|
TJC, median (IQR)
|
0 (−1; −1)
|
0 (−1; −1)
|
−1 (−1; 0)
|
0.28
|
SJC, median (IQR)
|
0 (0)
|
0 (0)
|
0 (0)
|
–
|
Patient-VAS, mm, median (IQR)
|
5 (−5; 10)
|
0 (−10; 10)
|
13 (9; 15)
|
<0.01
|